Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

In a report released today, Peter Lawson from Barclays maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $3.50. The company’s shares closed yesterday at $4.19.

Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Syndax Pharmaceuticals, and Immunocore Holdings. According to TipRanks, Lawson has an average return of 7.9% and a 44.92% success rate on recommended stocks.

Currently, the analyst consensus on CytomX Therapeutics is a Moderate Buy with an average price target of $4.44, which is a 5.97% upside from current levels. In a report released on May 5, Jefferies also upgraded the stock to a Buy with a $8.00 price target.

CTMX market cap is currently $285.5M and has a P/E ratio of -246.47.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTMX in relation to earlier this year. Most recently, in March 2024, Sean A. McCarthy, the CEO of CTMX bought 109,768.00 shares for a total of $172,335.76.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics (CTMX) Company Description:

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.